Item 2.02. Results of Operations and Financial Condition.
On April 28, 2021, Alimera Sciences, Inc. (“Alimera”) issued a press release
regarding its results of operations and financial condition for the first
quarter ended March 31, 2021 as well as a corporate update. On April 29, 2021 at
9:00 A.M. ET, Alimera will host a conference call and a live webcast on the
Investor Relations section of its corporate website at http://www.alimerasciences.com.
During the conference call, Alimera’s executives will discuss the company’s
financial results for the first quarter ended March 31, 2021 and provide
commercial and other corporate updates, including the impact of the COVID-19
pandemic on Alimera. The full text of the press release, which includes
information regarding Alimera’s use of a non-GAAP financial measure, is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Various statements made during the conference call and webcast will or may be
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, regarding, among other things, Alimera’s
expectation that the ILUVIEN sales will rebound in the second quarter of 2021
despite the continuing COVID-19 pandemic. Such forward-looking statements are
based on current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change these expectations, and
could cause actual results to differ materially from those projected in these
forward-looking statements. Meaningful factors that could cause actual results
to differ include, but are not limited to, uncertainties associated with (a) the
continued effects of COVID-19 on the ability or willingness of patients to visit
their retina specialists for ILUVIEN injections; (b) current and future
governmental orders and policies adopted by healthcare facilities to address the
COVID-19 pandemic, and the duration of these limitations; (c) the recent
resurgence of the pandemic in both Europe and parts of the U.S.; (d) the
emergence of COVID-19 variants that may increase the transmissibility of the
coronavirus or be more deadly, or both; (e) the success or failure of the
vaccine campaigns in Alimera’s markets; (f) when in fact the pandemic will
subside enough to permit Alimera’s operations to return to its prior growth
trajectory, and whether Alimera will be able to achieve that goal when given
that opportunity; as well as the other factors discussed in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended
December 31, 2020, which is on file with the SEC and is available on the SEC’s
website at http://www.sec.gov. Additional factors will also be described in
those sections of Alimera’s Quarterly Report on Form 10-Q for the first quarter
of 2021, to be filed with the SEC soon.
In addition to the risks described above and in Alimera’s reports and other
filings with the SEC, other unknown or unpredictable factors also could affect
Alimera’s results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects on,
Alimera. Therefore, no assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved. All forward-looking
statements contained in the conference call and webcast and in the press release
are expressly qualified by the cautionary statements contained or referred to
herein and therein. These forward-looking statements speak only as of the date
of the conference call and webcast and the press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically declines any
obligation, to publicly update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.
The information in Item 2.02 of this Current Report on Form 8-K and the press
release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
Item 7.01. Regulation FD.
The conference call and webcast, and the press release, include or will include
a non-GAAP financial measure, Adjusted EBITDA. A reconciliation of this non-GAAP
financial measure to the comparable measure calculated and presented in
accordance with GAAP is included in Alimera’s press release issued April 28,
2021 and attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01 is being
“furnished” and not “filed” with the SEC for purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities under such section.
Furthermore, such information shall not be deemed incorporated by reference in
any filing under the Securities Act, or the Exchange Act, unless specifically
identified as being incorporated therein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description 99.1 Press Release of Alimera Sciences, Inc. dated April 28, 2021 104 Cover Page Interactive Data File (embedded within the inline XBRL document) ? 4
© Edgar Online, source Glimpses